Featured Article Academic Journal Main Category: Bones / Orthopedics Also Included In: Stem Cell Research Article Date: 23 Aug 2012 - 11:00 PDT Current ratings for: Osteoporosis Clue Found In Stem Cell Signalling Protein 1 (1 votes) These are the implications of a new study led by Harvard Medical School (HMS) that was published online in The Journal of Clinical Investigation on 13 August. Senior author Bjorn Olsen, Hersey Professor of Cell Biology at HMS, told the press about what they found: "It shifts the thinking about what controls the differentiation of stem cells to bone cells instead of fat cells, and how to make sure this mechanism stays active with aging." Bone is not a dead material: it is living tissue that is changing all the time, as it is continuously formed and reabsorbed. Osteoporosis is a common bone disease where bone tissue becomes progressively thinner, resulting in higher risk of fracture. It affects about 1 in 5 American women and is thought to be caused by stem cells that normally differentiate into bone-forming cells becoming fat cells instead over time. For the study, Olsen, who is professor of developmental biology and dean for research at Harvard School of … Continue reading →

AUSTIN, Texas, Aug. 23, 2012 (GLOBE NEWSWIRE) -- SmallCapVoice announced today that a new audio interview with International Stem Cell Corporation (ISCO) (www.internationalstemcell.com), a California-based biotechnology company focused on therapeutic and research products, is now available. The interview can be heard at http://smallcapvoice.com/blog/8-16-12-smallcapvoice-interview-with-international-stem-cell-corporation-otcbb-isco The interview includes an overview of the markets being targeted by ISCO and its subsidiary companies, the goals for the companies in 2012, and the major achievements of the companies to date. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell(TM). ISCO also produces and markets specialized cells and growth media for … Continue reading →

While a draft plank in the Republican Partys platform supporting a constitutional amendment banning abortion has gotten plenty of attention, so far unnoticed is another culture war provision tucked right alongside it an opposition to federal funding for embryonic stem cell research. We oppose the killing of embryos for their stem cells. We oppose Federal funding of embryonic stem cell research, the draft language reads, mirroring previous years platforms. Youd be forgiven for having dj vu from 2004, when stem cell research was at the top of the agenda of both parties and sparked fierce and emotional debate. Its completely vanished from the political scene since what happened? Stem cells used to be one of the big three social issues dividing Americans, along with abortion and gay rights. It was a cultural debate engulfing our country today, as then-Kansas Sen. and now Gov. Sam Brownback, a staunch social conservative, saidin 2004. The issue played a major role in that years presidential race, with Democrat John Kerry suggesting that millions of lives were at stake by President Bush preventing federal funds from going to the medical research. Bush, buoyed into office by the Christian right, opposed the taxpayer dollars going to … Continue reading →

CARLSBAD, CA--(Marketwire -08/23/12)- International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, announced today that Dr. Simon Craw, Executive Vice President of Business Development and Investor Relations, will present at the 2012 Southern California Investor Conference on Thursday, August 30, 2012, at 2:30 pm PT / 5:30 pm ET. The conference will be held at the Marriott Hotel in Newport Beach, California. Southern California Investor ConferenceDate: Thursday, August 30, 2012 Time: 2:30 pm PT / 5:30 pm ET Location: Marriott Hotel, Newport Beach, CA Please contact the conference organizers if you have an interest in attending these conferences or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email markmcp@mzgroup.us or phone 1-212-301-7130 to arrange a meeting with management. Conference participation is limited by capacity and registration is required. For more information on the conference, please visit the conference website at http://www.californiastocks.com. About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. … Continue reading →